Brasada Capital Management’s AbbVie ABBV Stock Holding History

Brasada Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,000	Closed	-$982K	–	140
2020 Q2	$982K	Buy	10,000 +4,000	+67%	+$352K	0.28%	75
2020 Q1	$457K	Buy	+6,000	New	+$511K	0.16%	90
2018 Q4	–	Sell	-147	Closed	-$14K	–	285
2018 Q3	$14K	Buy	+147	New	+$13.9K	﹤0.01%	259

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Brasada Capital Management's ABBV Position: Q3 2020 in Review

Brasada Capital Management sold out of AbbVie (ABBV) in Q3 2020, closing a stake of 10,000 shares — an estimated $982K sold.

Brasada Capital Management first reported a position in ABBV in Q3 2018 and held it in 3 quarters. The position peaked at $982K in Q2 2020. 2,366 funds tracked by Wall St. Rank hold ABBV as of Q3 2020.

Brasada Capital Management reported no remaining AbbVie position as of Q3 2020 after selling out during the quarter.
Brasada Capital Management sold 10,000 AbbVie shares in Q3 2020, an estimated $982K.
Brasada Capital Management first reported a position in AbbVie in Q3 2018 and held it in 3 quarters.
Brasada Capital Management's AbbVie position peaked at $982K in Q2 2020.
2,366 funds tracked by Wall St. Rank held AbbVie as of Q3 2020.

Based on Brasada Capital Management's 13F filing for Q3 2020, filed 4 Nov 2020.